Scarica l'app Stockscreener
2.57
16.83%
-0.52
Dopo l'orario di chiusura:
2.60
0.03
+1.17%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ESPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.09
Aprire:
$2.52
Volume 24 ore:
31.21M
Relative Volume:
4.81
Capitalizzazione di mercato:
$518.17M
Reddito:
$116.33M
Utile/perdita netta:
$-209.25M
Rapporto P/E:
-1.2123
EPS:
-2.12
Flusso di cassa netto:
$-135.49M
1 W Prestazione:
-11.38%
1M Prestazione:
+2.39%
6M Prestazione:
+142.45%
1 anno Prestazione:
+24.15%
Intervallo 1D:
$2.30
$2.6599
Intervallo di 1 settimana:
$2.30
$3.42
Portata 52W:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Nome
Esperion Therapeutics Inc
Settore
Telefono
734-887-3903
Indirizzo
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Confronta ESPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.57 | 623.01M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
143.49 | 63.27B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.31 | 45.67B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.04 | 39.27B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.21 | 23.02B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
448.93 | 20.66B | 3.08B | 1.24B | 1.07B | 25.61 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-18 | Iniziato | Goldman | Neutral |
| 2024-12-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-08-01 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2023-03-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Ripresa | BofA Securities | Neutral |
| 2023-02-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Downgrade | Stifel | Buy → Hold |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Downgrade | Jefferies | Buy → Hold |
| 2021-02-09 | Downgrade | Goldman | Neutral → Sell |
| 2021-01-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-10 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Ripresa | JP Morgan | Underweight |
| 2020-08-11 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Ripresa | BofA/Merrill | Buy |
| 2020-03-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-24 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2019-09-16 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-29 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-03-13 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Reiterato | Needham | Strong Buy |
| 2018-12-13 | Iniziato | Goldman | Sell |
| 2018-10-29 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Iniziato | BTIG Research | Buy |
| 2018-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-07-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Downgrade | BofA/Merrill | Buy → Underperform |
Mostra tutto
Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie
Esperion Therapeutics Inc. (ESPR) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap DownShould You Sell? - MarketBeat
Esperion Therapeutics’ Bold Move: Stock Offering at $2.50 - StocksToTrade
Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Esperion Therapeutics prices $75M public offering - MSN
Why Is Esperion Therapeutics Stock Sinking Premarket Today? - Stocktwits
Esperion Therapeutics Prices $75 Million Share Offering - MarketScreener
Esperion prices $75 million public offering of common stock By Investing.com - Investing.com Nigeria
Esperion prices public offering of 30 million shares at $2.50 each - MarketScreener
Esperion Therapeutics Announces Pricing of $75 Million Public Offering of Common Stock - Quiver Quantitative
$75M Raise — Esperion Prices 30M Shares to Fund Oral LDL‑C Program - Stock Titan
Esperion Announces Pricing of Public Offering of Common Stock - GlobeNewswire Inc.
Esperion Therapeutics Experiences Evaluation Revision Amidst Mixed Market Indicators and Performance Trends - Markets Mojo
Esperion announces proposed public offering of common stock - MarketScreener
ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up - MSN
Esperion launches public offering of common stock to raise capital By Investing.com - Investing.com Australia
Esperion Therapeutics tumbles after stock offering launch - TradingView
Esperion Announces Strategic Expansion Plans for Bempedoic Acid - TipRanks
Esperion launches proposed public offering of common stock; shares fall 21% (ESPR:NASDAQ) - Seeking Alpha
Esperion stock tumbles after announcing public offering - Investing.com
Esperion Announces Proposed Public Offering of Common Stock - Stock Titan
Will Esperion Therapeutics Inc. outperform the marketMarket Activity Recap & Stepwise Entry and Exit Trade Signals - newser.com
Will Esperion Therapeutics Inc. rebound enough to break evenRate Hike & Low Risk Entry Point Tips - newser.com
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL and NEXLIZET Prior to April 19, 2040 - MarketScreener
Is Esperion Therapeutics Inc. stock a buy on dipsJuly 2025 Weekly Recap & Safe Swing Trade Setups - newser.com
Esperion’s Share Surge Following Patent Lawsuit Settlement - StocksToTrade
Esperion Therapeutics Gains Traction with Settlement and Strategic Moves - timothysykes.com
Esperion’s Legal Victory Against Dr. Reddy’s Sparks Stock Surge - StocksToTrade
Esperion Shares Surge Amid Patent Lawsuit Settlement - timothysykes.com
Analyzing drawdowns of Esperion Therapeutics Inc. with statistical toolsPortfolio Update Summary & Stepwise Entry/Exit Trade Alerts - newser.com
Has Esperion Therapeutics Inc. found a price floorWeekly Market Summary & Weekly High Potential Stock Alerts - newser.com
Is Esperion Therapeutics Inc. stock attractive for hedge fundsOptions Play & Daily Profit Focused Stock Screening - newser.com
Will Esperion Therapeutics Inc. (0ET) stock see valuation expansion2025 Earnings Impact & Fast Gaining Stock Reports - newser.com
Why analysts raise outlook for Esperion Therapeutics Inc. (0ET) stockAnalyst Downgrade & Free Long-Term Investment Growth Plans - newser.com
What does recent volatility data suggest for Esperion Therapeutics Inc.July 2025 Drop Watch & Reliable Price Breakout Alerts - newser.com
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Esperion Therapeutics, Inc. (ESPR) and Lead Plaintiff Deadline: March 14, 2016 - ACCESS Newswire
Esperion Therapeutics Surges on Patent Settlement With Dr. Reddy’s - StocksToTrade
Esperion Shares Soar Amid Resolving Patent Dispute - timothysykes.com
Is Esperion Therapeutics Inc a good long term investmentEquity Performance Review & In-Depth Analyst Ratings Explained Simply - earlytimes.in
Esperion settles patent litigation with Dr. Reddy’s Laboratories By Investing.com - Investing.com Nigeria
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap UpTime to Buy? - MarketBeat
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. - GlobeNewswire
Esperion settles patent dispute with Dr. Reddy’s over cholesterol drugs - Seeking Alpha
Esperion Therapeutics Shares Rise After Blocking Generic Version of Cholesterol Drug - MarketScreener
Esperion settles patent litigation with Dr. Reddy’s Laboratories - Investing.com
Esperion Announces Settlement Agreement with Dr. Reddy’s Laboratories Regarding NEXLETOL and NEXLIZET Patent Litigation - Quiver Quantitative
Esperion reaches settlement agreement with ANDA filer - MarketScreener
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040 | Dow Theory Letters - FinancialContent
Esperion Therapeutics Inc Azioni (ESPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Esperion Therapeutics Inc Azioni (ESPR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Koenig Sheldon L. | President and CEO |
Sep 17 '25 |
Sale |
2.79 |
28,427 |
79,254 |
1,518,831 |
| Halladay Benjamin | Chief Financial Officer |
Sep 17 '25 |
Sale |
2.81 |
7,046 |
19,785 |
474,862 |
0.54%
0.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):